Catalytic Protein Inhibitors
Covalent Modifiers
JANUARY 13, 2024
Prof. Dr. Thomas Kodadek Angewandte Chemie International Edition 2024 e202316726 [link] Many of the highest priority targets in a wide range of disease states are difficult-to-drug proteins. The development of reversible small molecule inhibitors for the active sites of these proteins with sufficient affinity and residence time on-target is an enormous challenge.
Let's personalize your content